Antifungal prophylaxis and therapy in patients with hematological malignancies and hematopoietic stem cell transplant recipients

Expert Review of Anti-Infective Therapy

Volumn 8, Issue 12, 2010, Pages 1451-1466

  Almyroudis, Nikolaos G ^a,b   Segal, Brahm H ^a,b  

^a ROSWELL PARK CANCER INSTITUTE   (United States)

^b UNIVERSITY AT BUFFALO   (United States)

Author keywords

amphotericin B; azole; echinocandin; fungi; leukemia; transplant

Indexed keywords

AMPHOTERICIN B; AMPHOTERICIN B DEOXYCHOLATE; AMPHOTERICIN B DERIVATIVE; AMPHOTERICIN B LIPID COMPLEX; ANIDULAFUNGIN; CALCINEURIN INHIBITOR; CASPOFUNGIN; CYCLOPHOSPHAMIDE; ECHINOCANDIN; FLUCONAZOLE; FLUCYTOSINE; ITRACONAZOLE; KETOCONAZOLE; MICAFUNGIN; POSACONAZOLE; RAPAMYCIN; VINCA ALKALOID; VORICONAZOLE;

ACUTE GRAFT VERSUS HOST DISEASE; ACUTE GRANULOCYTIC LEUKEMIA; ACUTE KIDNEY FAILURE; ACUTE LEUKEMIA; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; AREA UNDER THE CURVE; ASPERGILLOSIS; ASPERGILLUS FUMIGATUS; BLOODSTREAM INFECTION; BRAIN DISEASE; CANCER SURVIVAL; CANDIDEMIA; CANDIDIASIS; CHRONIC GRAFT VERSUS HOST DISEASE; CLINICAL TRIAL; COCCIDIOIDOMYCOSIS; CONTINUOUS INFUSION; CRYPTOCOCCAL MENINGITIS; CRYPTOCOCCOSIS; CYTOMEGALOVIRUS INFECTION; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG MEGADOSE; DRUG METABOLISM; DRUG SAFETY; FEBRILE NEUTROPENIA; FUNGAL ENDOPHTHALMITIS; FUNGUS ISOLATION; FUSARIOSIS; GASTROINTESTINAL DISEASE; GRAFT RECIPIENT; HEMATOLOGIC MALIGNANCY; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HISTOPLASMOSIS; HUMAN; INFECTION RISK; INVASIVE ASPERGILLOSIS; INVASIVE CANDIDIASIS; MENINGITIS; MYCOSIS; MYELODYSPLASTIC SYNDROME; NEPHROTOXICITY; NONHUMAN; OVERALL SURVIVAL; PHOTOSENSITIVITY; PSEUDALLESCHERIASIS; REVIEW; SALT WASTING; SIDE EFFECT; SQUAMOUS CELL CARCINOMA; SYSTEMIC MYCOSIS; UREMIA; VISUAL DISORDER; ZYGOMYCOSIS;

AMPHOTERICIN B; ANTIFUNGAL AGENTS; AZOLES; CLINICAL TRIALS AS TOPIC; ECHINOCANDINS; FLUCONAZOLE; HEMATOLOGIC NEOPLASMS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; MYCOSES; YEASTS;

EID: 78650216356     PISSN: 14787210     EISSN: 17448336     Source Type: Journal    
DOI: 10.1586/eri.10.141     Document Type: Review

References (172)

1. McNeil MM, Nash SL, Hajjeh RA et al. Trends in mortality due to invasive mycotic diseases in the United States, 1980-1997. Clin. Infect. Dis. 33, 641-647 (2001).
2. Segal BH. Aspergillosis. N. Engl. J. Med. 360, 1870-1884 (2009).
3. Bow EJ, Loewen R, Cheang MS et al. Cytotoxic therapy-induced D-xylose malabsorption and invasive infection during remission-induction therapy for acute myeloid leukemia in adults. J. Clin. Oncol. 15, 2254-2261 (1997).
4. Gerson SL, Talbot GH, Hurwitz S et al. Prolonged granulocytopenia: the major risk factor for invasive pulmonary aspergillosis in patients with acute leukemia. Ann. Intern. Med. 100, 345-351 (1984).
5. Bhatti Z, Shaukat A, Almyroudis NG, Segal BH. Review of epidemiology, diagnosis, and treatment of invasive mould infections in allogeneic hematopoietic stem cell transplant recipients. Mycopathologia 162, 1-15 (2006).
6. Yuen KY, Woo PC, Ip MS et al. Stage-specifc manifestation of mold infections in bone marrow transplant recipients: risk factors and clinical signifcance of positive concentrated smears. Clin. Infect. Dis. 25, 37-42 (1997).
7. Baddley JW, Stroud T P, Salzman D, Pappas PG. Invasive mold infections in allogeneic bone marrow transplant recipients. Clin. Infect. Dis. 32, 1319-1324 (2001).
8. Grow WB, Moreb JS, Roque D et al. Late onset of invasive aspergillus infection in bone marrow transplant patients at a university hospital. Bone Marrow Transplant. 29, 15-19 (2002).
9. Marr KA, Carter RA, Boeckh M, Martin P, Corey L. Invasive aspergillosis in allogeneic stem cell transplant recipients: changes in epidemiology and risk factors. Blood 100, 4358-4366 (2002).
10. Jantunen E, Ruutu P, Niskanen LT et al. Incidence and risk factors for invasive fungal infections in allogeneic BMT recipients. Bone Marrow Transplant. 19, 801-808 (1997).
11. Wald A, Leisenring W, van Burik JA, Bowden RA. Epidemiology of Aspergillus infections in a large cohort of patients undergoing bone marrow transplantation. J. Infect. Dis. 175, 1459-1466 (1997).
12. Kontoyiannis DP, Marr KA, Park BJ et al. Prospective surveillance for invasive fungal infections in hematopoietic stem cell transplant recipients, 2001-2006: overview of the Transplant-Associated Infection Surveillance Network (TRANSNET) Database. Clin. Infect. Dis. 50, 1091-1100 (2010).
13. van Burik JA, Carter SL, Freifeld AG et al. Higher risk of cytomegalovirus and aspergillus infections in recipients of T cell-depleted unrelated bone marrow: ana lysis of infectious complications in patients treated with T cell depletion versus immunosuppressive therapy to prevent graft-versus-host disease. Biol. Blood Marrow Transplant 13, 1487-1498 (2007).
14. De Pauw B, Walsh TJ, Donnelly JP et al. Revised defnitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/ Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. Clin. Infect. Dis. 46, 1813-1821 (2008).
15. Martin SI, Marty FM, Fiumara K et al. Infectious complications associated with alemtuzumab use for lymphoproliferative disorders. Clin. Infect. Dis. 43, 16-24 (2006).
16. Nucci M, Marr KA, Queiroz-Telles F et al. Fusarium infection in hematopoietic stem cell transplant recipients. Clin. Infect. Dis. 38(9), 1237-1242 (2004).
17. Walsh TJ, Groll A, Hiemenz J et al. Infections due to emerging and uncommon medically important fungal pathogens. Clin. Microbiol. Infect. 10(Suppl. 1), 48-66 (2004).
18. Marr KA, Carter RA, Crippa F, Wald A, Corey L. Epidemiology and outcome of mould infections in hematopoietic stem cell transplant recipients. Clin. Infect. Dis. 34, 909-917 (2002). (Pubitemid 34229758)
19. Neofytos D, Horn D, Anaissie E et al. Epidemiology and outcome of invasive fungal infection in adult hematopoietic stem cell transplant recipients: ana lysis of Multicenter Prospective Antifungal Therapy (PATH) alliance registry. Clin. Infect. Dis. 48, 265-273 (2009).
20. Patterson TF, Kirkpatrick WR, White M et al. Invasive aspergillosis. Disease spectrum, treatment practices, and outcomes. I3 Aspergillus Study Group. Medicine (Baltimore) 79, 250-260 (2000).
21. Denning DW, Stevens DA. Antifungal and surgical treatment of invasive aspergillosis: review of 2,121 published cases [published erratum appears in Rev. Infect. Dis. 13(2), 345 (1991)]. Rev. Infect. Dis. 12, 1147-1201 (1990).
22. Bates DW, Su L, Yu DT et al. Mortality and costs of acute renal failure associated with amphotericin B therapy. Clin. Infect. Dis. 32, 686-693 (2001). (Pubitemid 32221925)
23. Wingard JR, Kubilis P, Lee L et al. Clinical signifcance of nephrotoxicity in patients treated with amphotericin B for suspected or proven aspergillosis. Clin. Infect. Dis. 29, 1402-1407 (1999).
24. Bates DW, Su L, Yu DT et al. Correlates of acute renal failure in patients receiving parenteral amphotericin B. Kidney Int. 60, 1452-1459 (2001). (Pubitemid 32960039)
25. Eriksson U, Seifert B, Schaffner A. Comparison of effects of amphotericin B deoxycholate infused over 4 or 24 hours: randomised controlled trial. Br. Med. J. 322, 579-582 (2001).
26. Wright DG, Robichaud KJ, Pizzo PA, Deisseroth AB. Lethal pulmonary reactions associated with the combined use of amphotericin B and leukocyte transfusions. N. Engl. J. Med. 304, 1185-1189 (1981).
27. Groll AH, Lyman CA, Petraitis V et al. Compartmentalized intrapulmonary pharmacokinetics of amphotericin B and its lipid formulations. Antimicrob. Agents Chemother. 50, 3418-3423 (2006).
28. Ostrosky-Zeichner L, Marr KA, Rex JH, Cohen SH. Amphotericin B: time for a new 'gold standard'. Clin. Infect. Dis. 37(3), 415-425 (2003).
29. Cagnoni PJ, Walsh TJ, Prendergast MM et al. Pharmacoeconomic ana lysis of liposomal amphotericin B versus conventional amphotericin B in the empirical treatment of persistently febrile neutropenic patients. J. Clin. Oncol. 18, 2476-2483 (2000).
30. Saad AH, DePestel DD, Carver PL. Factors infuencing the magnitude and clinical signifcance of drug interactions between azole antifungals and select immunosuppressants. Pharmacotherapy 26, 1730-1744 (2006).
31. Como JA, Dismukes WE. Oral azole drugs as systemic antifungal therapy [see comments]. N. Engl. J. Med. 330, 263-272 (1994).
32. Balkis MM, Leidich SD, Mukherjee PK, Ghannoum MA. Mechanisms of fungal resistance: an overview. Drugs 62, 1025-1040 (2002).
33. Segal BH, Baden LR, Brown AE et al. Prevention and treatment of cancer-related infections. J. Natl Compr. Canc. Netw. 6(2), 122-174 (2008).
34. Verweij PE, Mellado E, Melchers WJ. Multiple-triazole-resistant aspergillosis. N. Engl. J. Med. 356, 1481-1483 (2007).
35. Snelders E, van der Lee HA, Kuijpers J et al. Emergence of azole resistance in Aspergillus fumigatus and spread of a single resistance mechanism. PLoS Med. 5, e219 (2008).
36. Verweij PE, Snelders E, Kema GH, Mellado E, Melchers WJ. Azole resistance in Aspergillus fumigatus: a side-effect of environmental fungicide use? Lancet Infect. Dis. 9, 789-795 (2009).
37. Baddley JW, Marr KA, Andes DR et al. Patterns of susceptibility of Aspergillus isolates recovered from patients enrolled in the Transplant-Associated Infection Surveillance Network. J. Clin. Microbiol. 47, 3271-3275 (2009).
38. Almyroudis NG, Sutton DA, Fothergill AW, Rinaldi MG, Kusne S. In vitro susceptibilities of 217 clinical isolates of zygomycetes to conventional and new antifungal agents. Antimicrob. Agents Chemother. 51, 2587-2590 (2007).
39. Poirier JM, Cheymol G. Optimisation of itraconazole therapy using target drug concentrations. Clin. Pharmacokinet. 35, 461-473 (1998).
40. Ahmad SR, Singer SJ, Leissa BG. Congestive heart failure associated with itraconazole. Lancet 357, 1766-1767 (2001).
41. Vfend®, package insert. Pfzer, NY, USA.
42. Pascual A, Nieth V, Calandra T et al. Variability of voriconazole plasma levels measured by new high-performance liquid chromatography and bioassay methods. Antimicrob. Agents Chemother. 51, 137-143 (2007).
43. Triflio S, Pennick G, Pi J et al. Monitoring plasma voriconazole levels may be necessary to avoid subtherapeutic levels in hematopoietic stem cell transplant recipients. Cancer 109, 1532-1535 (2007).
44. Smith J, Safdar N, Knasinski V et al. Voriconazole therapeutic drug monitoring. Antimicrob. Agents Chemother. 50, 1570-1572 (2006).
45. Pascual A, Calandra T, Bolay S et al. Voriconazole therapeutic drug monitoring in patients with invasive mycoses improves efficacy and safety outcomes. Clin. Infect. Dis. 46, 201-211 (2008).
46. Tan K, Brayshaw N, Tomaszewski K, Troke P, Wood N. Investigation of the potential relationships between plasma voriconazole concentrations and visual adverse events or liver function test abnormalities. J. Clin. Pharmacol. 46, 235-243 (2006).
47. Walsh TJ, Pappas P, Winston DJ et al Voriconazole compared with liposomal amphotericin B for empirical antifungal therapy in patients with neutropenia and persistent fever. N. Engl. J. Med. 346, 225-234 (2002). (Pubitemid 34438861)
48. Herbrecht R, Denning DW, Patterson TF et al. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N. Engl. J. Med. 347, 408-415 (2002). (Pubitemid 34851833)
49. Frick MA, Soler-Palacin P, Nalda AM, Guarner ME, Nadal CF. Photosensitivity in immunocompromised patients receiving long-term therapy with oral voriconazole. Pediatr. Infect. Dis. J. 29, 480-481 (2010).
50. McCarthy KL, Playford EG, Looke DF, Whitby M. Severe photosensitivity causing multifocal squamous cell carcinomas secondary to prolonged voriconazole therapy. Clin. Infect. Dis. 44, e55-e56 (2007).
51. Marty FM, Cosimi LA, Baden LR. Breakthrough zygomycosis after voriconazole treatment in recipients of hematopoietic stem-cell transplants. N. Engl. J. Med. 350, 950-952 (2004).
52. Imhof A, Balajee SA, Fredricks DN, Englund JA, Marr KA. Breakthrough fungal infections in stem cell transplant recipients receiving voriconazole. Clin. Infect. Dis. 39(5), 743-746 (2004).
53. Kontoyiannis DP, Lionakis MS, Lewis RE et al. Zygomycosis in a tertiary care cancer center in the era of aspergillus-active antifungal therapy: a case control observational study of 27 recent cases. J. Infect. Dis. 191, 1350-1360 (2005).
54. Gubbins PO, Krishna G, Sansone-Parsons A et al. Pharmacokinetics and safety of oral posaconazole in neutropenic stem cell transplant recipients. Antimicrob. Agents Chemother. 50, 1993-1999 (2006).
55. Ullmann AJ, Cornely OA, Burchardt A et al. Pharmacokinetics, safety, and efficacy of posaconazole in patients with persistent febrile neutropenia or refractory invasive fungal infection. Antimicrob. Agents Chemother. 50, 658-666 (2006).
56. Conte JE Jr, Golden JA, Krishna G et al. Intrapulmonary pharmacokinetics and pharmacodynamics of posaconazole at steady state in healthy subjects. Antimicrob Agents Chemother. 53, 703-707 (2009).
57. Cornely OA, Maertens J, Winston DJ et al Posaconazole vs. fuconazole or itraconazole prophylaxis in patients with neutropenia. N. Engl. J. Med. 356, 348-359 (2007).
58. Ullmann AJ, Lipton JH, Vesole DH et al Posaconazole or fuconazole for prophylaxis in severe graft-versus-host disease. N. Engl J. Med. 356, 335-347 (2007).
59. Bowman JC, Hicks PS, Kurtz MB et al The antifungal echinocandin caspofungin acetate kills growing cells of Aspergillus fumigatus in vitro. Antimicrob. Agents Chemother. 46, 3001-3012 (2002).
60. Balashov SV, Park S, Perlin DS. Assessing resistance to the echinocandin antifungal drug caspofungin in Candida albicans by profling mutations in FKS1. Antimicrob. Agents Chemother. 50, 2058-2063 (2006).
61. Gardiner RE, Souteropoulos P, Park S, Perlin DS. Characterization of Aspergillus fumigatus mutants with reduced susceptibility to caspofungin. Med. Mycol 43(Suppl. 1), S299-S305 (2005).
62. Gumbo T. Impact of pharmacodynamics and pharmacokinetics on echinocandin dosing strategies. Curr. Opin. Infect. Dis. 20, S587-S591 (2007).
63. Nguyen TH, Hoppe-Tichy T, Geiss HK et al. Factors infuencing caspofungin plasma concentrations in patients of a surgical intensive care unit. J. Antimicrob Chemother. 60, 100-106 (2007).
64. Walsh TJ, Adamson PC, Seibel NL et al Pharmacokinetics, safety, and tolerability of caspofungin in children and adolescents. Antimicrob. Agents Chemother. 49, 4536-4545 (2005).
65. Seibel NL, Schwartz C, Arrieta A et al Safety, tolerability, and pharmacokinetics of Micafungin (FK463) in febrile neutropenic pediatric patients. Antimicrob. Agents Chemother. 49, 3317-3324 (2005).
66. Hope WW, Seibel NL, Schwartz CL et al. Population pharmacokinetics of micafungin in pediatric patients and implications for antifungal dosing. Antimicrob. Agents Chemother. 51, 3714-3719 (2007).
67. Queiroz-Telles F, Berezin E, Leverger G et al. Micafungin versus liposomal amphotericin B for pediatric patients with invasive candidiasis: substudy of a randomized double-blind trial. Pediatr. Infect. Dis. J. 27, 820-826 (2008).
68. Benjamin DK Jr, Driscoll T, Seibel NL et al Safety and pharmacokinetics of intravenous anidulafungin in children with neutropenia at high risk for invasive fungal infections. Antimicrob. Agents Chemother. 50, 632-638 (2006).
69. Gumbo T, Drusano GL, Liu W et al Once-weekly micafungin therapy is as effective as daily therapy for disseminated candidiasis in mice with persistent neutropenia. Antimicrob. Agents Chemother. 51, 968-974 (2007).
70. Wiederhold NP, Kontoyiannis DP, Chi J et al. Pharmacodynamics of caspofungin in a murine model of invasive pulmonary aspergillosis: evidence of concentration-dependent activity J. Infect. Dis. 190, 1464-1471 (2004).
71. Stevens DA, White TC, Perlin DS, Selitrennikoff CP. Studies of the paradoxical effect of caspofungin at high drug concentrations. Diagn. Microbiol Infect. Dis. 51, 173-178 (2005).
72. Pappas PG, Kauffman CA, Andes D et al Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America. Clin. Infect. Dis. 48, 503-535 (2009).
73. Rex JH, Bennett JE, Sugar AM et al. A randomized trial comparing fuconazole with amphotericin B for the treatment of candidemia in patients without neutropenia. Candidemia Study Group and the National Institute [see comments]. N. Engl. J. Med. 331, 1325-1330 (1994).
74. Pfaller MA, Jones RN, Messer SA, Edmond MB, Wenzel RP. National surveillance of nosocomial blood stream infection due to species of Candida other than Candida albicans: frequency of occurrence and antifungal susceptibility in the SCOPE Program. SCOPE Participant Group. Surveillance and Control of Pathogens of Epidemiologic. Diagn. Microbiol. Infect. Dis. 30, 121-129 (1998).
75. Pfaller MA, Diekema DJ, Jones RN, Messer SA, Hollis RJ. Trends in antifungal susceptibility of Candida spp. isolated from pediatric and adult patients with bloodstream infections: SENTRY Antimicrobial Surveillance Program, 1997 to 2000. J. Clin. Microbiol. 40, 852-856 (2002).
76. Rex JH, Pappas PG, Karchmer AW et al. A randomized and blinded multicenter trial of high-dose fuconazole plus placebo versus fuconazole plus amphotericin B as therapy for candidemia and its consequences in nonneutropenic subjects. Clin. Infect. Dis. 36, 1221-1228 (2003).
77. Kullberg BJ, Sobel JD, Ruhnke M et al. Voriconazole versus a regimen of amphotericin B followed by fuconazole for candidaemia in non-neutropenic patients: a randomised non-inferiority trial. Lancet 366, 1435-1442 (2005).
78. Pfaller MA, Diekema DJ, Gibbs DL et al. Results from the ARTEMIS DISK Global Antifungal Surveillance study, 1997 to 2005: an 8.5-year ana lysis of susceptibilities of Candida species and other yeast species to fuconazole and voriconazole determined by CLSI standardized disk diffusion testing. J. Clin. Microbiol. 45, 1735-1745 (2007).
79. Pfaller MA, Messer SA, Boyken L et al. Selection of a surrogate agent (fuconazole or voriconazole) for initial susceptibility testing of posaconazole against Candida spp., Results from a global antifungal surveillance program. J. Clin. Microbiol. 46, 551-559 (2008).
80. Mora-Duarte J, Betts R, Rotstein C et al. Comparison of caspofungin and amphotericin B for invasive candidiasis. N. Engl. J. Med. 347, 2020-2029 (2002).
81. Kuse ER, Chetchotisakd P, da Cunha CA et al. Micafungin versus liposomal amphotericin B for candidaemia and invasive candidosis: a Phase III randomised double-blind trial. Lancet 369, 1519-1527 (2007).
82. Reboli AC, Rotstein C, Pappas PG et al. Anidulafungin versus fuconazole for invasive candidiasis. N. Engl. J. Med. 356, 2472-2482 (2007).
83. Pappas PG, Rotstein CM, Betts RF et al. Micafungin versus caspofungin for treatment of candidemia and other forms of invasive candidiasis. Clin. Infect. Dis. 45, 883-893 (2007).
84. Tavanti A, Davidson AD, Gow NA, Maiden MC, Odds FC. Candida orthopsilosis and Candida metapsilosis spp. nov. To replace Candida parapsilosis groups II and III. J. Clin. Microbiol. 43, 284-292 (2005).
85. Barchiesi F, Spreghini E, Tomassetti S et al. Effects of caspofungin against Candida guilliermondii and Candida parapsilosis. Antimicrob. Agents Chemother. 50, 2719-2727 (2006).
86. Legrand F, Lecuit M, Dupont B et al Adjuvant corticosteroid therapy for chronic disseminated candidiasis. Clin. Infect. Dis. 46, 696-702 (2008).
87. Walsh TJ, Anaissie EJ, Denning DW et al Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America. Clin. Infect. Dis. 46, 327-360 (2008).
88. Schwartz S, Ruhnke M, Ribaud P et al Improved outcome in central nervous system aspergillosis, using voriconazole treatment. Blood 106, 2641-2645 (2005).
89. Walsh TJ, Lutsar I, Driscoll T et al Voriconazole in the treatment of aspergillosis, scedosporiosis, and other invasive fungal infections in children. Pediatr. Infect. Dis. J. 21, 240-248 (2002).
90. Steinbach WJ, Benjamin DK Jr, Kontoyiannis DP et al. Infections due to Aspergillus terreus: a multicenter retrospective ana lysis of 83 cases. Clin. Infect. Dis. 39(2), 192-198 (2004).
91. Bowden R, Chandrasekar P, White MH et al. A double-blind, randomized, controlled trial of amphotericin B colloidal dispersion versus amphotericin B for treatment of invasive aspergillosis in immunocompromised patients. Clin. Infect. Dis. 35(4), 359-366 (2002).
92. Perfect JR. Treatment of non-Aspergillus moulds in immunocompromised patients, with amphotericin B lipid complex. Clin. Infect. Dis. 40(Suppl. 6), S401-S408 (2005).
93. Chandrasekar PH, Ito JI. Amphotericin B lipid complex in the management of invasive aspergillosis in immunocompromised patients. Clin. Infect. Dis. 40(Suppl. 6), S392-S400 (2005).
94. Alexander BD, Wingard JR. Study of renal safety in amphotericin B lipid complex-treated patients. Clin. Infect. Dis. 40(Suppl. 6), S414-S421 (2005).
95. Cornely OA, Maertens J, Bresnik M et al Liposomal amphotericin B as initial therapy for invasive mold infection: a randomized trial comparing a high-loading dose regimen with standard dosing (AmBiLoad trial). Clin. Infect. Dis. 44, 1289-1297 (2007).
96. Hong Y, Shaw PJ, Nath CE et al. Population pharmacokinetics of liposomal amphotericin B in pediatric patients with malignant diseases. Antimicrob. Agents Chemother. 50, 935-942 (2006).
97. Walsh TJ, Raad I, Patterson TF et al. Treatment of invasive aspergillosis with posaconazole in patients who are refractory to or intolerant of conventional therapy: an externally controlled trial. Clin. Infect. Dis. 44, 2-12 (2007).
98. Maertens J, Raad I, Petrikkos G et al Efficacy and safety of caspofungin for treatment of invasive aspergillosis in patients refractory to or intolerant of conventional antifungal therapy. Clin. Infect. Dis. 39(11), 1563-1571 (2004).
99. Herbrecht R, Maertens J, Baila L et al Caspofungin first-line therapy for invasive aspergillosis in allogeneic hematopoietic stem cell transplant patients: a European Organisation for Research and Treatment of Cancer study. Bone Marrow Transplant. 45, 1227-1233 (2010).
100. Viscoli C, Herbrecht R, Akan H et al. An EORTC Phase II study of caspofungin as first-line therapy of invasive aspergillosis in haematological patients. J. Antimicrob. Chemother. 64, 1274-1281 (2009).
101. Denning DW, Marr KA, Lau WM et al Micafungin (FK463), alone or in combination with other systemic antifungal agents, for the treatment of acute invasive aspergillosis. J. Infect. 53, 337-349 (2006).
102. Kontoyiannis DP, Ratanatharathorn V, Young JA et al. Micafungin alone or in combination with other systemic antifungal therapies in hematopoietic stem cell transplant recipients with invasive aspergillosis. Transpl. Infect. Dis. 11, 89-93 (2009).
103. Marr KA, Boeckh M, Carter RA, Kim HW, Corey L. Combination antifungal therapy for invasive aspergillosis. Clin. Infect. Dis. 39(6), 797-802 (2004).
104. Maertens J, Glasmacher A, Herbrecht R et al. Multicenter, noncomparative study of caspofungin in combination with other antifungals as salvage therapy in adults with invasive aspergillosis. Cancer 107, 2888-2897 (2006).
105. Roden MM, Zaoutis TE, Buchanan WL et al. Epidemiology and outcome of zygomycosis: a review of 929 reported cases. Clin. Infect. Dis. 41, 634-653 (2005).
106. Greenberg RN, Mullane K, van Burik JA et al. Posaconazole as salvage therapy for zygomycosis. Antimicrob. Agents Chemother. 50, 126-133 (2006).
107. van Burik JA, Hare RS, Solomon HF, Corrado ML, Kontoyiannis DP. Posaconazole is effective as salvage therapy in zygomycosis: a retrospective summary of 91 cases. Clin. Infect. Dis. 42, e61-e65 (2006).
108. Boelaert JR, de Locht M, Van Cutsem J et al. Mucormycosis during deferoxamine therapy is a siderophore-mediated infection. In vitro and in vivo animal studies. J. Clin. Invest. 91, 1979-1986 (1993).
109. Ibrahim AS, Gebermariam T, Fu Y et al. The iron chelator deferasirox protects mice from mucormycosis through iron starvation. J. Clin. Invest. 117, 2649-2657 (2007).
110. Spellberg B, Andes D, Perez M et al. Safety and outcomes of open-label deferasirox iron chelation therapy for mucormycosis. Antimicrob. Agents Chemother. 53, 3122-3125 (2009).
111. Reed C, Bryant R, Ibrahim AS et al. Combination polyene-caspofungin treatment of rhino-orbital-cerebral mucormycosis. Clin. Infect. Dis. 47, 364-371 (2008).
112. Nucci M, Anaissie E. Emerging fungi. Infect. Dis. Clin. North Am. 20, 563-579 (2006).
113. Nucci M, Anaissie E. Fusarium infections in immunocompromised patients. Clin. Microbiol. Rev. 20, 695-704 (2007).
114. Perfect JR, Marr KA, Walsh TJ et al. Voriconazole treatment for less-common, emerging, or refractory fungal infections. Clin. Infect. Dis. 36, 1122-1131 (2003).
115. Raad II, Hachem RY, Herbrecht R et al. Posaconazole as salvage treatment for invasive fusariosis in patients with underlying hematologic malignancy and other conditions. Clin. Infect. Dis. 42, 1398-1403 (2006).
116. Revankar SG, Patterson JE, Sutton DA, Pullen R, Rinaldi MG. Disseminated phaeohyphomycosis: review of an emerging mycosis. Clin. Infect. Dis. 34, 467-476 (2002).
117. Rodriguez-Tudela JL, Berenguer J, Guarro J et al. Epidemiology and outcome of Scedosporium prolifcans infection, a review of 162 cases. Med. Mycol. 47, 359-370 (2009).
118. Cuenca-Estrella M, Gomez-Lopez A, Mellado E et al. Head-to-head comparison of the activities of currently available antifungal agents against 3378 Spanish clinical isolates of yeasts and flamentous fungi. Antimicrob. Agents Chemother. 50, 917-921 (2006).
119. Revankar SG, Sutton DA, Rinaldi MG. Primary central nervous system phaeohyphomycosis: a review of 101 cases. Clin. Infect. Dis. 38, 206-216 (2004).
120. Segal BH, Almyroudis NG, Battiwalla M et al. Prevention and early treatment of invasive fungal infection in patients with cancer and neutropenia and in stem cell transplant recipients in the era of newer broad-spectrum antifungal agents and diagnostic adjuncts. Clin. Infect. Dis. 44, 402-409 (2007).
121. Gonzalez AV, Ullmann AJ, Almyroudis NG, Segal BH. Broad-spectrum antifungal prophylaxis in patients with cancer at high risk for invasive mold infections: point. J. Natl Compr. Canc. Netw. 6, 175-182 (2008).
122. Maertens J, Buve K, Anaissie E. Broad-spectrum antifungal prophylaxis in patients with cancer at high risk for invasive mold infections, counterpoint. J. Natl Compr. Canc. Netw. 6, 183-189 (2008).
123. De Pauw BE, Donnelly JP. Prophylaxis and aspergillosis - has the principle been proven? N. Engl. J. Med. 356, 409-411 (2007).
124. Marr KA, Seidel K, White TC, Bowden RA. Candidemia in allogeneic blood and marrow transplant recipients, evolution of risk factors after the adoption of prophylactic fuconazole. J. Infect. Dis. 181, 309-316 (2000).
125. Bodey GP, Mardani M, Hanna HA et al. The epidemiology of Candida glabrata and Candida albicans fungemia in immunocompromised patients with cancer. Am. J. Med. 112, 380-385 (2002).
126. Mattiuzzi GN, Estey E, Raad I et al. Liposomal amphotericin B versus the combination of fuconazole and itraconazole as prophylaxis for invasive fungal infections during induction chemotherapy for patients with acute myelogenous leukemia and myelodysplastic syndrome. Cancer 97, 450-456 (2003).
127. Mattiuzzi GN, Kantarjian H, Faderl S et al. Amphotericin B lipid complex as prophylaxis of invasive fungal infections in patients with acute myelogenous leukemia and myelodysplastic syndrome undergoing induction chemotherapy. Cancer 100, 581-589 (2004). (Pubitemid 38124777)
128. Morgenstern GR, Prentice AG, Prentice HG et al. A randomized controlled trial of itraconazole versus fuconazole for the prevention of fungal infections in patients with haematological malignancies. U.K. Multicentre Antifungal Prophylaxis Study Group. Br. J. Haematol. 105, 901-911 (1999).
129. Menichetti F, Del Favero A, Martino P et al. Itraconazole oral solution as prophylaxis for fungal infections in neutropenic patients with hematologic malignancies: a randomized, placebo-controlled, double-blind, multicenter trial. GIMEMA Infection Program. Gruppo Italiano Malattie Ematologiche dell' Adulto. Clin. Infect. Dis. 28, 250-255 (1999).
130. Harousseau JL, Dekker AW, Stamatoullas-Bastard A et al. Itraconazole oral solution for primary prophylaxis of fungal infections in patients with hematological malignancy and profound neutropenia: a randomized, double-blind, double-placebo, multicenter trial comparing itraconazole and amphotericin B. Antimicrob. Agents Chemother. 44, 1887-1893 (2000).
131. Marr KA, Crippa F, Leisenring W et al. Itraconazole versus fuconazole for prevention of fungal infections in allogeneic stem cell transplant patients. Blood 2, 2 (2003).
132. Winston DJ, Maziarz RT, Chandrasekar PH et al. Intravenous and oral itraconazole versus intravenous and oral fuconazole for long-term antifungal prophylaxis in allogeneic hematopoietic stem-cell transplant recipients. A multicenter, randomized trial. Ann. Intern. Med. 138, 705-713 (2003).
133. van Burik JA, Ratanatharathorn V, Stepan DE et al. Micafungin versus fuconazole for prophylaxis against invasive fungal infections during neutropenia in patients undergoing hematopoietic stem cell transplantation. Clin. Infect. Dis. 39, 1407-1416 (2004).
134. Marr KA, Leisenring W, Crippa F et al. Cyclophosphamide metabolism is impacted by azole antifungals. Blood 22, 22 (2003).
135. Tomblyn M, Chiller T, Einsele H et al. Guidelines for preventing infectious complications among hematopoietic cell transplantation recipients: a global perspective. Biol. Blood Marrow Transplant 15, 1143-1238 (2009).
136. Cordonnier C, Pautas C, Maury S et al. Empirical versus preemptive antifungal therapy for high-risk, febrile, neutropenic patients: a randomized, controlled trial. Clin. Infect. Dis. 48, 1042-1051 (2009).
137. Wingard JR, Carter SL, Walsh TJ et al. Randomized double-blind trial of fuconazole versus voriconazole for prevention of invasive fungal infection (IFI) after allo hematopoietic cell transplantation (HCT). Blood DOI: blood-2010-02-268151v1-blood-2010-02-268151 (2010) (Epub ahead of print).
138. Rijnders BJ, Cornelissen JJ, Slobbe L et al. Aerosolized liposomal amphotericin B for the prevention of invasive pulmonary aspergillosis during prolonged neutropenia: a randomized, placebo-controlled trial. Clin. Infect. Dis. 46, 1401-1408 (2008).
139. Alexander BD, Dodds Ashley ES, Addison RM et al. Non-comparative evaluation of the safety of aerosolized amphotericin B lipid complex in patients undergoing allogeneic hematopoietic stem cell transplantation. Transpl. Infect. Dis. 8, 13-20 (2006).
140. Suarez F, Lortholary O, Buland S et al. Detection of circulating Aspergillus fumigatus DNA by real-time PCR assay of large serum volumes improves early diagnosis of invasive aspergillosis in high-risk adult patients under hematologic surveillance. J. Clin. Microbiol. 46, 3772-3777 (2008).
141. Cuenca-Estrella M, Meije Y, Diaz-Pedroche C et al. Value of serial quantifcation of fungal DNA by a real-time PCR-based technique for early diagnosis of invasive aspergillosis in patients with febrile neutropenia. J. Clin. Microbiol. 47, 379-384 (2009).
142. Francesconi A, Kasai M, Petraitiene R et al. Characterization and comparison of galactomannan enzyme immunoassay and quantitative real-time PCR assay for detection of Aspergillus fumigatus in bronchoalveolar lavage fuid from experimental invasive pulmonary aspergillosis. J. Clin. Microbiol. 44, 2475-2480 (2006).
143. Fedorova ND, Khaldi N, Joardar VS et al. Genomic islands in the pathogenic flamentous fungus Aspergillus fumigatus. PLoS Genet 4, e1000046 (2008).
144. Steinbach WJ, Reedy JL, Cramer RA Jr, Perfect JR, Heitman J. Harnessing calcineurin as a novel anti-infective agent against invasive fungal infections. Nat. Rev. Microbiol. 5, 418-430 (2007).
145. Segal BH, Steinbach WJ. Combination antifungals: an update. Expert Rev. Anti Infect. Ther. 5, 883-892 (2007).
146. Pachl J, Svoboda P, Jacobs F et al. A randomized, blinded, multicenter trial of lipid-associated amphotericin B alone versus in combination with an antibody-based inhibitor of heat shock protein 90 in patients with invasive candidiasis. Clin. Infect. Dis. 42, 1404-1413 (2006).
147. Cowen LE, Lindquist S. Hsp90 potentiates the rapid evolution of new traits: drug resistance in diverse fungi. Science 309, 2185-2189 (2005).
148. Kontoyiannis DP. Decrease in the number of reported cases of zygomycosis among patients with diabetes mellitus: a hypothesis. Clin. Infect. Dis. 44, 1089-1090 (2007).
149. Segal BH, Kwon-Chung J, Walsh TJ et al. Immunotherapy for fungal infections. Clin. Infect. Dis. 42, 507-515 (2006).
150. Lewis RE, Chamilos G, Prince RA, Kontoyiannis DP. Pretreatment with empty liposomes attenuates the immunopathology of invasive pulmonary aspergillosis in corticosteroid-immunosuppressed mice. Antimicrob. Agents Chemother. 51, 1078-1081 (2007).
151. Bellocchio S, Gaziano R, Bozza S et al. Liposomal amphotericin B activates antifungal resistance with reduced toxicity by diverting Toll-like receptor signalling from TLR-2 to TLR-4. J. Antimicrob. Chemother. 55, 214-222 (2005).
152. Wheeler RT, Fink GR. A drug-sensitive genetic network masks fungi from the immune system. PLoS Pathog 2, e35 (2006).
153. Hohl TM, Feldmesser M, Perlin DS, Pamer EG. Caspofungin modulates infammatory responses to Aspergillus fumigatus through stage-specifc effects on fungal beta-glucan exposure. J. Infect. Dis. 198, 176-185 (2008).
154. Lamaris GA, Lewis RE, Chamilos G et al. Caspofungin-mediated b-glucan unmasking and enhancement of human polymorphonuclear neutrophil activity against aspergillus and non-aspergillus hyphae. J. Infect. Dis. 198, 186-192 (2008).
155. Walsh TJ, Karlsson MO, Driscoll T et al. Pharmacokinetics and safety of intravenous voriconazole in children after single- or multiple-dose administration. Antimicrob. Agents Chemother. 48, 2166-2172 (2004).
156. Walsh TJ, Driscoll TA, Groll AH et al. Population pharmacokinetic (POP-PK) ana lysis of voriconazole (VRC): developing a rationale for dosage in pediatric patients. Presented at: 47th Interscience Conference on Antimicrobial Agents and Chemotherapy. Chicago, IL, USA, 17-20 September 2007.
157. Anaissie EJ, Darouiche RO, Abi-Said D et al. Management of invasive candidal infections: results of a prospective, randomized, multicenter study of fuconazole versus amphotericin B and review of the literature. Clin. Infect. Dis. 23, 964-972 (1996).
158. van der Horst CM, Saag MS, Cloud GA et al. Treatment of cryptococcal meningitis associated with the acquired immunodeficiency syndrome. National Institute of Allergy and Infectious Diseases Mycoses Study Group and AIDS Clinical Trials Group N. Engl. J. Med. 337, 15-21 (1997).
159. Saag MS, Cloud GA, Graybill JR et al. A comparison of itraconazole versus fuconazole as maintenance therapy for AIDS-associated cryptococcal meningitis. National Institute of Allergy and Infectious Diseases Mycoses Study Group [see comments]. Clin. Infect. Dis. 28, 291-296 (1999).
160. Leenders AC, Reiss P, Portegies P et al. Liposomal amphotericin B (AmBisome) compared with amphotericin B both followed by oral fuconazole in the treatment of AIDS-associated cryptococcal meningitis. AIDS 11, 1463-1471 (1997).
161. Chen SC. Cryptococcosis in Australasia and the treatment of cryptococcal and other fungal infections with liposomal amphotericin B. J. Antimicrob. Chemother. 49(Suppl. 1), 57-61 (2002).
162. Perfect JR, Dismukes WE, Dromer F et al. Clinical practice guidelines for the management of cryptococcal disease: 2010 update by the Infectious Diseases Society of America. Clin. Infect. Dis. 50, 291-322 (2010).
163. Singh N, Perfect JR. Immune reconstitution syndrome and exacerbation of infections after pregnancy. Clin. Infect. Dis. 45, 1192-1199 (2007). (Pubitemid 47580319)
164. Sungkanuparph S, Filler SG, Chetchotisakd P et al. Cryptococcal immune reconstitution infammatory syndrome after antiretroviral therapy in AIDS patients with cryptococcal meningitis: a prospective multicenter study. Clin. Infect. Dis. 49, 931-934 (2009).
165. Galgiani JN, Ampel NM, Blair JE et al. IDSA Guidelines: coccidioidomycosis. Clin. Infect. Dis. 41, 1217-1223 (2005).
166. Dewsnup DH, Galgiani JN, Graybill JR et al. Is it ever safe to stop azole therapy for Coccidioides immitis meningitis? Ann. Intern. Med. 124, 305-310 (1996).
167. Johnson PC, Wheat LJ, Cloud GA et al. Safety and efficacy of liposomal amphotericin B compared with conventional amphotericin B for induction therapy of histoplasmosis in patients with AIDS. Ann. Intern. Med. 137, 105-109 (2002).
168. Wheat LJ, Cloud G, Johnson PC et al. Clearance of fungal burden during treatment of disseminated histoplasmosis with liposomal amphotericin B versus itraconazole. Antimicrob. Agents Chemother. 45, 2354-2357 (2001).
169. Wheat LJ, Connolly P, Haddad N et al. Antigen clearance during treatment of disseminated histoplasmosis with itraconazole versus fuconazole in patients with AIDS. Antimicrob. Agents Chemother. 46, 248-250 (2002).
170. Wheat LJ, Freifeld AG, Kleiman MB et al. Clinical practice guidelines for the management of patients with histoplasmosis: 2007 update by the Infectious Diseases Society of America. Clin. Infect. Dis. 45, 807-825 (2007).
171. Chapman SW, Bradsher RW Jr, Campbell GD Jr, Pappas PG, Kauffman CA. Practice guidelines for the management of patients with blastomycosis. Infectious Diseases Society of America. Clin. Infect. Dis. 30, 679-683 (2000).
172. Kauffman CA, Bustamante B, Chapman SW, Pappas PG. Clinical practice guidelines for the management of sporotrichosis: 2007 update by the Infectious Diseases Society of America. Clin. Infect. Dis. 45, 1255-1265 (2007).